Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclopentolate cycloplegia delivery tolerability study in healthy adults
ACTRN12626001159347Phase 2Not yet recruiting
- Sponsor
- Queensland University of Technology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclopentolate in cycloplegia (6 arms), sponsored by Queensland University of Technology. Primary endpoints: Tolerability: sting, Tolerability: bulbar conjunctival redness and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cyclopentolate
03
Conditions
cycloplegia
Beyond the preview
Go deeper on ACTRN12626001159347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001159347.